BL Pharmtech Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 04:34 am EDT
Share
BL Pharmtech Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 26,139.05 million compared to KRW 18,183.41 million a year ago. Net loss was KRW 5,186.06 million compared to KRW 4,776.67 million a year ago. Basic loss per share from continuing operations was KRW 58 compared to KRW 54 a year ago. Diluted loss per share from continuing operations was KRW 58 compared to KRW 54 a year ago. Basic loss per share was KRW 58 compared to KRW 54 a year ago.
For the six months, sales was KRW 0.00002 million compared to KRW 0.00003 million a year ago. Net loss was KRW 5,223.16 million compared to KRW 5,173.77 million a year ago. Basic loss per share from continuing operations was KRW 59 compared to KRW 58 a year ago. Diluted loss per share from continuing operations was KRW 59 compared to KRW 58 a year ago. Basic loss per share was KRW 59 compared to KRW 58 a year ago.
BL PharmTech Corp, formerly Next BT Co Ltd, is a Korea-based company primarily engaged in the manufacture and sale of health foods. The Company operates its business through four segments. The Health Functional Food Business segment is engaged in the manufacture and sale of products such as red ginsengs, diet foods and vitamins. The Cosmetics Business segment is engaged in the manufacture and sale of anti-aging skincare products and, among others. The Diagnostic and Medical Business segment is engaged in the manufacture and sale of diagnostic kits and other products. The Other segment is engaged in the distribution of health foods and other products.
BL PHARMTECH CORP. 
